The Australian company has used one of the world’s largest cancer research stages to sharpen its pitch that oncolytic RNA immunotherapies could materially shift outcomes in some of the most difficult-to-treat tumours. …
Early signals strengthen Australian company's case for next generation cancer immunotherapies
April 22, 2026 Australian Biotech
Latest Video
New Stories
-
Opthea returns to ASX and works to restart eye therapy candidate
June 5, 2026 - - Latest News -
A clear disconnect between the public and private on 'Most Favored Nation' pricing
June 5, 2026 - - Latest News -
New blueprint charts a potential policy path forward on biosimilars
June 4, 2026 - - Latest News -
Officials cite company consultation, system changes, and spending approvals to justify delay
June 4, 2026 - - Latest News -
Novo Nordisk's Marie Krogh Prize returns and crosses the Tasman to back early career women in science
June 4, 2026 - - Latest News -
Study confirms pharmacist led care expands timely access to urinary tract infection treatment and contraception
June 4, 2026 - - BioPharma -
Officials talk down the prospect of MFN impact on the PBS
June 4, 2026 - - Latest News